why does Pharma exclude 'poor prognosis' patients from trials?
It comes down to 💰. If pts stop due to comorbid reasons, it adds more deviation in the outcome measure. So they need a larger trial to show statistical significance.
Should we require sponsors to include PS 2/3, Hgb<9, real-world pts in Phase 3 trials?